Get the Stockscreener App
10.13
0.00%
0.00
Iteos Therapeutics Inc stock is traded at $10.13, with a volume of 2.59M.
It is up +0.00% in the last 24 hours and down -0.39% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$10.13
Open:
$10.12
24h Volume:
2.59M
Relative Volume:
1.87
Market Cap:
$447.80M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-3.2159
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
-0.78%
1M Performance:
-0.39%
6M Performance:
+44.71%
1Y Performance:
-41.65%
1-Day Range:
$10.11
$10.14
1-Week Range:
$10.11
$10.22
52-Week Range:
$4.80
$17.63
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.13 | 447.80M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-14-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-13-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
How to use Fibonacci retracement on iTeos Therapeutics Inc.July 2025 Reactions & Verified Stock Trade Ideas - Newser
How to integrate iTeos Therapeutics Inc. into portfolio analysis tools2025 Trade Ideas & Real-Time Stock Price Movement Reports - Newser
What institutional flow reveals about iTeos Therapeutics Inc.Long Setup & Stepwise Entry and Exit Trade Signals - Newser
Real time social sentiment graph for iTeos Therapeutics Inc.Share Buyback & Community Consensus Trade Alerts - Newser
Developing predictive dashboards with iTeos Therapeutics Inc. data2025 Valuation Update & Stepwise Entry and Exit Trade Signals - Newser
Historical volatility pattern of iTeos Therapeutics Inc. visualized2025 Pullback Review & AI Driven Price Forecasts - Newser
What technical models suggest about iTeos Therapeutics Inc.’s comebackMarket Activity Recap & Verified Swing Trading Watchlists - Newser
iTeos Therapeutics Inc. stock trend outlook and recovery pathInsider Buying & Fast Gain Stock Trading Tips - Newser
Using data filters to optimize entry into iTeos Therapeutics Inc.Trade Risk Report & Expert Approved Momentum Trade Ideas - Newser
Custom watchlist performance reports with iTeos Therapeutics Inc.Market Sentiment Report & Short-Term High Return Strategies - Newser
Applying Elliott Wave Theory to iTeos Therapeutics Inc.2025 Market WrapUp & Low Drawdown Investment Ideas - Newser
Using Python tools to backtest iTeos Therapeutics Inc. strategiesJuly 2025 Trade Ideas & Free Risk Controlled Daily Trade Plans - Newser
iTeos Therapeutics Inc. stock momentum explainedWeekly Trend Recap & Low Risk Entry Point Guides - Newser
What earnings revisions data tells us about iTeos Therapeutics Inc.2025 Institutional Moves & Short-Term Trading Alerts - Newser
iTeos Therapeutics Inc. stock retracement – recovery analysisJuly 2025 Volume & Reliable Price Breakout Alerts - Newser
Is iTeos Therapeutics Inc. stock reversal real or fakeJuly 2025 PostEarnings & Weekly Hot Stock Watchlists - Newser
What MACD and RSI say about iTeos Therapeutics Inc.2025 Stock Rankings & Real-Time Chart Pattern Alerts - Newser
Automated trading signals detected on iTeos Therapeutics Inc.2025 Support & Resistance & Momentum Based Trading Signals - Newser
Key metrics from iTeos Therapeutics Inc.’s quarterly data2025 Investor Takeaways & Safe Capital Growth Stock Tips - Newser
Can iTeos Therapeutics Inc. lead its sector in growthJuly 2025 Catalysts & Risk Controlled Daily Trade Plans - theviewers.co.kr
Is now the right time to enter iTeos Therapeutics Inc.Quarterly Investment Review & AI Driven Stock Movement Reports - theviewers.co.kr
Published on: 2025-08-23 10:17:55 - Newser
Intraday Charts Show Spike in iTeos Therapeutics Inc. ActivityJuly 2025 Retail & Long-Term Capital Growth Ideas - classian.co.kr
Halper Sadeh Investigates iTeos Therapeutics and WK Kellogg Sales. - AInvest
Published on: 2025-08-20 06:11:33 - Newser
Published on: 2025-08-19 22:05:02 - Newser
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):